Finzati - Logo
QNRX logo

Quoin Pharmaceuticals, Ltd.

QNRX • Biotechnology
$0.00
— 0.00 (0.00%)
EarningsLatest report: Mar 31, 2026
HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$10.22M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0Healthy liquidity · 3.61Weak profitability
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 7, 2026, 12:00 AM UTCLast profile update: Aug 16, 2026, 12:17 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.00
Change0.00%
Market Cap$10.22M
52W Range3.25 - 41.80
Beta1.66
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio3.61
Quick Ratio3.61
Volume64.68K

Investment DNA

How strong this company looks for long-term investors

40
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
70/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
55/100
Why this score▼
Manageable debt level · 0Healthy liquidity · 3.61Weak profitability
Analyst view
No analyst data available now.

Company Overview

IPO: 8/1/2016
Industry: Biotechnology
P/B i: 1.65
Debt / Equity i: 0.00
Operating Margin: 0.00%
Net Margin: 0.00%
ROE i: -
ROIC: -

Financial Health

Score14 / 20
Debt / Equity: 0.00
Current Ratio: 3.61
Quick Ratio: 3.61
Status: Good

Insider Transactions

Recent executive and insider activity

Stonepine Capital Management, LLC
Transaction: 03/26/2026
OTHER
Change
0
Price
Not reported
Filing
03/31/2026
Type
OTHER
Leong Natalie Ee Mun
Transaction: 02/04/2026
BUY
Change
+12,211
Price
$7.37
Filing
02/06/2026
Type
BUY
SEMBER MICHAEL T
Transaction: 02/04/2026
BUY
Change
+8,141
Price
$7.37
Filing
02/06/2026
Type
BUY